COVID-19 Update: mRNA COVID-19 Vaccines and Myocarditis

The FDA has required the manufacturers of the mRNA COVID-19 vaccines Comirnaty (Pfizer-BioNTech) and Spikevax (Moderna) to revise their labels to include updated information about the risks of myocarditis/pericarditis. The revised labels state that the risks of myocarditis and pericarditis, with onset of symptoms typically in the first week following vaccination, are highest in males 12-24 years old.